The Longevity Podcast: Optimizing HealthSpan & MindSpan

Alzheimer’s Is Also A Vascular Disease

Dung Trinh

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 19:49

Send us Fan Mail

Alzheimer’s has been sold to all of us as a neuron story: plaques, tangles, and brain cells fading away. But the data we walk through here points to a more unsettling possibility that the real tipping point is structural. When the brain’s blood vessels fail, memory can fall apart even faster, and what looks like “classic Alzheimer’s dementia” may actually be a vascular collapse hiding in plain sight.

We unpack a large autopsy analysis from the NACC database and use it to zoom in on cerebral amyloid angiopathy (CAA), where amyloid beta doesn’t just sit in brain tissue but builds up inside vessel walls. That shift changes everything. We explain the amyloid overflow hypothesis, how perivascular drainage pathways get overwhelmed with age, and why brittle arteries can set off microinfarcts that quietly sever brain networks over years. We also dig into a key double dissociation: CAA drives cortical microinfarcts, while hypertension-related arteriolosclerosis drives deep subcortical injury, meaning blood pressure control is essential but not the whole answer for Alzheimer’s-related vascular damage.

Then we go one layer deeper into genetics and the neurovascular unit. APOE ε4 shows up not only as an amyloid risk factor, but as a threat to blood-brain barrier integrity, letting proteins like fibrinogen leak into the brain and ignite microglia-driven inflammation. Finally, we connect these mechanisms to the new era of anti-amyloid monoclonal antibodies, ARIA risk, and why clearing plaques without accounting for “the state of the pipes” may limit real-world cognitive benefit.

If this reframes how you think about Alzheimer’s disease, vascular dementia, CAA, microinfarcts, and precision medicine, subscribe, share this with a friend, and leave a review. What do you think matters more for preventing dementia: removing amyloid or protecting brain blood vessels?

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

The Plumbing Twist On Alzheimer’s

SPEAKER_00

Imagine um peering into the brain of someone suffering from severe Alzheimer's. You'd probably expect to find just a wasteland of plaques and tangles, right?

SPEAKER_01

Yeah, that's the classic expectation.

SPEAKER_00

Right. But what if I told you the real culprit, like the thing actually stealing their memories, wasn't a brain cell problem at all, but well, a plumbing disaster. What if everything you thought you knew about the most infamous memory thief on the planet is actually missing half the story?

SPEAKER_01

It requires a really profound shift in perspective. Because for decades, I mean, the medical community has operated on this incredibly strict neurocentric model.

SPEAKER_00

To focus on the brain cells.

SPEAKER_01

Exactly. The diagnostic criteria have been heavily anchored to the presence of those signature amyloid plaques and tau tangles. If the pathology report confirms those proteins are there, the conclusion has historically been just, well, very straightforward. The disease is Alzheimer's.

SPEAKER_00

But today, our mission for this deep dive is to shatter that assumption entirely. We are going to uncover the hidden vascular side of cognitive decline. We're going to explore why cure Alzheimer's is actually incredibly rare, and why the ultimate trigger for dementia might just be the structural failure of the brain's own blood vessels.

SPEAKER_01

It's a massive shift in how we look at the brain.

SPEAKER_00

It really is.

Autopsy Data That Challenges Assumptions

SPEAKER_00

And to do this, we are untacking a really groundbreaking 2026 paper from the Journal of Prevention of Alzheimer's disease. The lead author, Min Yao Yu, alongside this massive research team, analyzed autopsy data from 3,791 participants. And this is all from the National Alzheimer's Coordinating Center, or NACC database. Aaron Ross Powell Right.

SPEAKER_01

And the sheer scale of the NACC database is really what makes these findings so robust. I mean, when you have nearly 4,000 clinical pathological records, you can finally separate the noise from the signal. So I want you to imagine the backdrop behind me right now, like a vibrant, illuminated cityscape at night.

SPEAKER_00

Okay, I'm picturing it.

SPEAKER_01

Now picture all the buildings which represent the neurons just fading away. They go completely dark, leaving only this glowing, pulsing network of roads, highways, and subway tunnels. Oh wow. Yeah. That is exactly what this study forces us to do. It shifts our focus strictly to the infrastructure, you know, the supply lines. And the data completely reshapes our framework through understanding how cognitive decline actually takes hold in the brain.

SPEAKER_00

Okay, let's untack this.

CAA Explained In Plain Language

SPEAKER_00

We need to start with this concept of cerebral amyloid angiopathy, or CAA. The paper points out that up to 90% of individuals with an Alzheimer's diagnosis also have severe CAA. I mean, a 90% overlap is definitely not a coincidence.

SPEAKER_01

No, not at all. It suggests these two conditions are fundamentally intertwined. Right. They are deeply connected by the exact same toxic protein, but the mechanism of damage is totally different. We traditionally track amyloid beta as it as it clumps together in the brain tissue.

SPEAKER_00

Forming those famous plaques.

SPEAKER_01

But in CAA, the amyloid doesn't just remain isolated in the tissue, it actively infiltrates and builds up inside the actual walls of the blood vessels themselves.

SPEAKER_00

Wait, inside the wall?

SPEAKER_01

Inside the walls. Specifically, it targets the cortical and leptomaningeal arteries, which form the vital vascular network, supplying the outer, highly active cognitive layers of your brain.

SPEAKER_00

So if we think about the brain's waste clearance, like a city's sanitation system, having amyloid in the tissue is like garbage piling up in the city parks. But CAA is what happens when that garbage gets stuffed directly into the city's clumbing system.

SPEAKER_01

That's a perfect analogy.

SPEAKER_00

You aren't just making the environment toxic, you are fundamentally compromising the pipes themselves. Like they are going to warp, back up, and eventually just burst.

SPEAKER_01

Aaron Powell Exactly. What's fascinating here is the mechanism driving that breakdown, which researchers call the amyloid

How Amyloid Gets Stuck In Walls

SPEAKER_01

overflow hypothesis. You see, the brain is an intensely metabolic organ, right? It's producing waste constantly. Normally the perivacular drainage pathways, which are these microscopic tunnels running alongside your blood vessels, they flush this waste out.

SPEAKER_00

Like tiny storm drains.

SPEAKER_01

Right. Exactly like storm drains. And the actual pulsing of your arteries acts as a mechanical pump to keep that fluid moving. But when amyloid production spikes or um the clearance mechanisms become sluggish with age, those pathways get completely overwhelmed.

SPEAKER_00

The system jams, the protein can't get out, so it just gets lodged in the exit route.

SPEAKER_01

It gets trapped right inside the vessel walls. And amyloid is structurally toxic to the smooth muscle cells that give arteries their elasticity. So as those smooth muscle cells undergo apoptosis and died off, the vessel walls become rigid, fragile, and leaky. It fails completely, which only worsens the clearance problem, creating this vicious cycle of structural

Microinfarcts And Network Collapse

SPEAKER_01

decay.

SPEAKER_00

Aaron Powell Which brings us to the actual consequences of having fragile clogged pipes in your brain. To figure out how this vascular damage impacts the patient, the researchers used a statistical framework called structural equation modeling, or SEMEM, and this isn't just like looking for simple correlations, right?

SPEAKER_01

Aaron Powell No. SCM is designed to map out complex multi-step chain reactions. It helps determine if A directly causes C or if A actually causes B, which then causes C. Got it. Tracing those indirect pathways is crucial in an organ as complex as the brain. The sim analysis revealed a staggering dynamic, honestly. Over half of the effect, 56.1% to be exact, that amyloid burden has on microvascular injury is indirectly mediated strictly through CAA.

SPEAKER_00

Wait, really? So the amyloid plaques in the tissue aren't doing the majority of the structural damage on their own?

SPEAKER_01

Not directly, no.

SPEAKER_00

Aaron Powell The real damage occurs because the amyloid invades the vessel walls, causes the CAA, and then that brittle vascular state leads to what the paper calls microinfarcs. Aaron Powell Right.

SPEAKER_01

And microinfarcs are basically microscopic ischemic strokes. Tiny regions of tissue where the blood supply is completely choked off, leading to localized cellular death.

SPEAKER_00

Okay, I have to play devil's advocate here, though. If these microinfarcs are entirely microscopic, like so small that they are routinely invisible to conventional MRI scans, how much damage can they really do? It seems like we might be overstating the impact of such tiny localized lesions when the brain is so massive.

SPEAKER_01

It's a totally fair question, but that assumes the brain functions as a collection of isolated islands rather than a highly integrated network. Okay. Think of it like a global telecommunications grid. You don't need to drop a bomb on a massive data center to disrupt the network. You just need to snip thousands of microscopic fiber optic cables connecting the servers.

SPEAKER_00

Ah, I see.

SPEAKER_01

A microinfarct might be tiny, but if it severs a critical communication relay between the hippocampus and the prefrontal cortex, the downstream functional loss is massive.

SPEAKER_00

It's death by a thousand cuts, the network just degrades until it can't transmit the signal anymore.

SPEAKER_01

Precisely. And we have to consider the reality of how neuropathologists actually examine the brain. At autopsy, they only sample a minuscule fraction of the total brain volume, often just a few small blocks of tissue.

SPEAKER_00

So if they find them there.

SPEAKER_01

If they are consistently finding these microscopic strokes in those tiny random samples, statistical probability dictates that the entire brain is heavily riddled with them. It implies that vast neural networks have been systematically disconnected over years.

SPEAKER_00

So if you're listening to this and you meticulously take your blood pressure medication every morning and do your daily cardio, you might be thinking you're fully protecting your brain's blood vessels from this kind of stroke damage. But this study looks closely at that assumption by searching

Two Different Stroke Pathways

SPEAKER_00

for a double dissociation.

SPEAKER_01

Yes, the double dissociation finding is critical here.

SPEAKER_00

And for those who might not know, a double dissociation is when you prove that two seemingly similar problems are actually driven by two completely independent, non-overlapping mechanisms.

SPEAKER_01

Right. And the researchers found a remarkably clear double dissociation in the autosy data. They demonstrated that severe CAA was the overwhelming driver for cortical microinfarcks.

SPEAKER_00

The strokes on the outer layers.

SPEAKER_01

Exactly. The strokes happening in the outer layers of the brain responsible for higher level cognitive processing. The adjusted odds ratio was 2.96. Conversely, arteriolosclerosis, which is the thickening of vessel walls driven by traditional high blood pressure, had virtually no link to those cortical strokes.

SPEAKER_00

Really? None?

SPEAKER_01

Virtually none. Arteriolosclerosis was the primary driver for deep subcortical microinfarts located near the center of the brain with an odds ratio of 2.46. But CAA didn't cause those deep strokes.

SPEAKER_00

So what does this all mean? Does this imply that traditional advice like taking blood pressure medication won't actually protect a patient from this specific Alzheimer's-related vascular damage?

SPEAKER_01

Aaron Powell Well, managing hypertension is obviously critical for protecting the deep brain structures in your heart. But yes, managing hypertension will not stop the CAA microinfarct cascade. We are looking at two completely separate neighborhoods of the brain being actively destroyed by two completely separate pathogenic processes.

SPEAKER_00

Wow. That runs completely counter to what most people assume about blood pressure and strokes.

SPEAKER_01

It does. You can't just lower the pressure in the pipes to save them when you were dealing with a toxic protein that is rotting the pipes for the inside out. It requires an entirely different strategy for building vascular resilience.

SPEAKER_00

Here's where it gets

APOE E4 And Blood Brain Barrier Leaks

SPEAKER_00

really interesting, though. Because this raises the question of vulnerability. I mean, Alzheimer's is notoriously heterogeneous. Two patients can have the exact same burden of amyloid plaques, but exhibit vastly different rates of cognitive decline.

SPEAKER_01

Yes, and the paper points directly to genetics to explain this variance, specifically highlighting the APOE epsilon-4 allele.

SPEAKER_00

That's a famous one.

SPEAKER_01

It is. It's the strongest genetic risk factor for sporadic Alzheimer's disease. But historically, the focus has been on how this gene variant either increases amyloid production or decreases its clearance from the brain tissue. What this study brings to light is how uniquely devastating the epsilon-4 allele is to the structural integrity of the blood vessels themselves.

SPEAKER_00

The enrichment data in the study is intense. Among the patients who developed CAA, there was a massive overrepresentation of the epsilon-4 gene compared to the patients whose vessels remain clear.

SPEAKER_01

Right. There's a stark dose-dependent relationship. 43.3% of the CAA group carried one epsilon-4 copy, and 11.8% carried two. Compare that to just 22.8% and 1.9% in the non-CAA group.

SPEAKER_00

That is a massive difference. Having the APOE epsilon-4 gene is um it's like having a genetic return-to-sender malfunction. Not only do you produce more trash with the amyloid, but your blood-brain barrier's export system is broken, trapping the toxic waste right inside those fragile pipes.

SPEAKER_01

That's a brilliant way to phrase it. The normal APOE protein is essentially a lipid transporter. It binds to amyloid to help shuttle it across the blood brain barrier for disposal. But the mutated Epsilon-4 version of this protein is structurally inefficient. It binds poorly to amyloid, and it actually competes with amyloid for the same exit receptors on the blood vessels.

SPEAKER_00

It's like having a defective garbage disposal in your kitchen sink. Like the motor runs, but the blades are totally dull. Instead of flushing the waste down the drain smoothly, it just shreds the amyloid into this sticky paste that coats and eventually bursts the pipes under your sink. The export system is fundamentally broken.

SPEAKER_01

Exactly. And that buildup leads to a catastrophic failure of the blood-brain barrier. The researchers noted that for any given severity level of CAA, the patients carrying the APOE epsilon-4 gene experience a much steeper, far more aggressive trajectory of cognitive decline than the non-carriers.

SPEAKER_00

Wait, so even if a non-carrier and an epsilon-4 carrier have the exact same amount of amyloid physically stuck in their vessels, the epsilon-4 carrier loses their memory significantly faster.

SPEAKER_01

Significantly faster, yes.

SPEAKER_00

There has to be a mechanical reason for that accelerated decline.

SPEAKER_01

There is. The reason lies in the neurovascular unit. When amyloid gets stuck in the vessel walls of an epsilon-4 carrier, the blood-brain barrier doesn't just stiffen, it severely leaks. It allows neurotoxic plasma proteins from the bloodstream, specifically proteins like fibrinogen, which is involved in blood clotting, to spill directly into the brain tissue.

SPEAKER_00

And let's dig into why that matters, because blood obviously doesn't belong in the brain. The brain is an immune-privileged organ, right? It operates behind a strict security checkpoint, completely isolated from the body's normal immune system.

SPEAKER_01

That isolation is essential for survival. The brain has its own resident immune cells called microglia, which normally exist in a quiet, resting state, just gently pruning synapses and maintaining the environment. But when a plasma protein like fibrinogen crosses the breached blood-brain barrier.

SPEAKER_00

Oh, I see where this is going.

SPEAKER_01

Yeah, those microglia detected as an alien invasion.

SPEAKER_00

They chammoc.

SPEAKER_01

They transition immediately into an aggressive phagocytic state. They release massive amounts of inflammatory cytokines and neurotoxins designed to destroy the perceived invader. But in doing so, they cause massive collateral damage to the surrounding healthy neurons. Wow. So for these genetically vulnerable individuals, CAA isn't just a mechanical blockage causing a tiny localized stroke. It is a biological trigger that sets off a massive, highly destructive immune system fire that burns through healthy tissue far beyond the actual blood vessel.

SPEAKER_00

That is horrifying. You have the waste backing

The Triple Hit Threshold For Dementia

SPEAKER_00

up, the pipes leaking, and then an immune system fire burning down the remaining infrastructure.

SPEAKER_01

It is a cascading failure.

SPEAKER_00

And to measure the clinical toll of this cascading failure, the researchers used a metric called the CDR sum of boxes, or CDRSB. It's an 18-point scale that assesses memory, orientation, personal care, and problem solving, right? Where a higher score indicates more severe dementia.

SPEAKER_01

Correct. And when you look at the autopsy profiles alongside these final clinical scores, the reality of the data is striking. The researchers isolated a pure AD group, which were patients who had a massive burden of Alzheimer's plaques and tangles in their tissue, but whose blood vessels were remarkably clean.

SPEAKER_00

No CAA, no microinfarx.

SPEAKER_01

Exactly. And that pure AD group had an adjusted mean CDRSB score of 9.8.

SPEAKER_00

Which means they certainly had significant memory loss and cognitive impairment.

SPEAKER_01

Yes. But when the researchers looked at the triple HIIT group.

SPEAKER_00

The patients who had the Alzheimer's plaques, plus the severe CAA clogging their vessels, plus the resulting structural microinfarx.

SPEAKER_01

Right. Their cognitive decline didn't just inch up, it fell off a cliff. The triple hit group suffered a profound cognitive collapse with a score of 11.5.

SPEAKER_00

Wow. That statistical jump is huge.

SPEAKER_01

It is the clinical difference between a patient needing some moderate assistance with their daily finances or managing their schedule versus a patient losing their functional independence entirely and requiring round-the-clock total care.

SPEAKER_00

This perfectly illustrates what researchers call the threshold model of dementia. It turns out the human brain is shockingly resilient. Like it can actually tolerate a surprising amount of Alzheimer's protein pathology if its structural architecture and blood supply remain perfectly intact.

SPEAKER_01

We have spent decades focused so intensely on the plaques themselves, assuming they are the sole direct drivers of the cognitive loss. But this data argues that a huge portion of what we diagnose clinically as Alzheimer's dementia is actually the functional expression of this triple hit.

SPEAKER_00

If the plumbing holds up, the brain can endure the garbage, but once the plumbing breaks down, the entire city falls.

SPEAKER_01

Exactly. It is the mixed vascular pathology that finally pushes the neural network past its compensatory threshold, causing the system to crash. And if we connect this to the bigger picture, this is why it

New Amyloid Drugs And ARIA Risk

SPEAKER_01

matters to you right now.

SPEAKER_00

Because of the new drugs.

SPEAKER_01

Right. We are currently navigating a new era of Alzheimer's therapeutics. For the first time, we have FDA-approved monoclonal antibodies. These are drugs designed to aggressively bind to and clear amyloid plaques out of the brain tissue.

SPEAKER_00

Which, on the surface, sounds like a total victory. If amyloid is the garbage and these drugs are sweeping the parks clean, that should halt the disease. But based on the mechanisms we just explored, there is a massive biological catch.

SPEAKER_01

Aaron Powell There is. When these monoclonal antibodies clear the plaques from the brain tissue, they are fundamentally altering the state of the amyloid. They break down the inert plaques and mobilize the protein into a soluble form so it can be flushed out.

SPEAKER_00

Oh no.

SPEAKER_01

But it has to exit through the perivascular drainage pathways, the exact same plumbing system we've been discussing.

SPEAKER_00

So you are taking a massive amount of amyloid from the tissue and pushing it directly into the drainage pipes. If a patient already has sevue CAA like, if their blood vessels are already rigid, brittle, and clogged with old amyloid, and you suddenly push a massive wave of newly mobilized amyloid through that compromised system.

SPEAKER_01

The pipes cannot handle the volume. Clinically, this manifests as ARA or amyloid-related imaging abnormalities. Because the vessels are already degraded, this sudden influx of mobilized amyloid causes the blood-brain barrier to fail catastrophically. Fluid leaks out into the brain, causing severe swelling, and in many cases the brittle vessels physically rupture, causing microhemorrhages.

SPEAKER_00

It's essentially inducing the exact vascular trauma we've been talking about, but at an accelerated rate.

SPEAKER_01

ARA is a known, heavily monitored side effect of these new drugs. But beyond the immediate safety concerns of brain swelling, this study raises a profound question about the long-term efficacy of just clearing plaques. If we successfully clear the upstream tissue, but we do it in a brain where the downstream blood vessels are already severely destroyed by CAA and thousands of microinfarcs, how much actual cognitive benefit will that patient experience?

SPEAKER_00

You can clean all the garbage out of the park, but if the city's power grid is down and the water mains are shattered, the city is still fundamentally unlivable. Treating the plaques without actively respecting the state of the pipes might drastically limit how much we can actually alter the trajectory of the disease.

SPEAKER_01

It strongly suggests that our clinical trials need to evolve. If we do not aggressively stratify patients based on their baseline vascular copathology, we might be entirely missing the true picture. We need to know the state of the infrastructure before we start moving the heavy cargo.

Precision Medicine And The Big Question

SPEAKER_00

Let's summarize the incredible journey this data just took us on. We started by looking at the classic neurocentric view of Alzheimer's, the idea that it's purely a cellular problem, a disease of plaques and tangles. But by diving into the pathology of nearly 4,000 individuals, we've uncovered a devastating triple hit against the brain's physical infrastructure.

SPEAKER_01

A completely new perspective.

SPEAKER_00

We've seen how amyloid overflows into the blood vessels to cause CAA, rotting the smooth muscle. We've seen how that structural failure chokes off the blood supply, causing thousands of microscopic strokes that systematically disconnect the neural network. And we've explored how the APOE epsilon-4 gene acts as a biological amplifier, breaking the blood-brain barrier and turning a plumbing issue into a fiery inflammatory disaster zone.

SPEAKER_01

It demands that the future of Alzheimer's treatment must pivot toward true precision medicine. We have to simultaneously target the proteinopathy while actively fortifying the neurovascular unit. We simply cannot treat the brain cells while ignoring the supply lines that keep them alive.

SPEAKER_00

It is a completely new battleground for neuroscience, which leaves you with a fascinating, almost paradoxical thought to ponder long after this deep dive ends. If the data clearly shows that the human brain can actually tolerate Alzheimer's plaques surprisingly well as long as the blood vessels stay healthy and structurally intact, could the ultimate cure for dementia not be clearing the amylote at all, but rather finding a way to make our brain's vascular plumbing completely indestructible?